Neurocrine Bioscience Stock
€107.90
Your prediction
Neurocrine Bioscience Stock
Pros and Cons of Neurocrine Bioscience in the next few years
Pros
Cons
Performance of Neurocrine Bioscience vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Neurocrine Bioscience | -0.360% | -2.132% | -17.916% | 2.275% | -9.556% | 34.572% | 17.795% |
| Ironwood Pharmaceuticals | 1.510% | 6.316% | 3.061% | -51.030% | -60.392% | -60.392% | -54.185% |
| Arrowhead Pharmaceuticals Inc. | 4.280% | -1.604% | -9.199% | -28.986% | -33.576% | -66.102% | -29.548% |
| Novocure Ltd | -2.190% | 1.503% | -2.218% | -12.320% | 11.173% | -85.811% | -77.946% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Neurocrine Biosciences (NASDAQ: NBIX), a company operating in the Biotechnology & Medical Research industry, showcases an interesting financial outlook. The company's financials indicate a growing revenue base and a healthy mix of both current and non-current assets. However, there are also aspects where the company could potentially face challenges, warranting a deeper analysis of its financial standing.
Growing Revenue: Neurocrine has consistently increased its revenue over the past three years, with total revenues of $1.05 billion in 2020, $1.13 billion in 2021, and $1.49 billion in 2022. This reflects a strong demand for the company's products and services.
Increasing Gross Profit: The gross profit has seen a continuous upward trend with $1.04 billion in 2020, $1.12 billion in 2021, and $1.47 billion in 2022. This suggests that the company is efficiently managing its cost of revenue, enabling higher profitability.
Comments
News
Why Neurocrine Biosciences Stock Was Tumbling This Week
Neurocrine Biosciences (NASDAQ: NBIX) had some major news to report several days ago, but it was hardly beneficial to the company's stock. The latest information from the lab dampened enthusiasm for
